Patrik Vitazka
Overview
Explore the profile of Patrik Vitazka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
3772
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garrido C, Manoogian M, Ghambire D, Lucas S, Karnoub M, Olson M, et al.
Virchows Arch
. 2023 Oct;
484(6):1005-1014.
PMID: 37857998
In DESTINY-Breast04 (DB-04), safety and efficacy of HER2-targeted antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) in previously treated HER2-low unresectable/metastatic breast cancer were established. This manuscript describes the analytical validation of...
2.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al.
N Engl J Med
. 2022 Jun;
387(1):9-20.
PMID: 35665782
Background: Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available...
3.
Li B, Smit E, Goto Y, Nakagawa K, Udagawa H, Mazieres J, et al.
N Engl J Med
. 2021 Sep;
386(3):241-251.
PMID: 34534430
Background: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have not been approved for patients with non-small-cell lung cancer (NSCLC). The efficacy and safety of trastuzumab deruxtecan (formerly DS-8201), a...
4.
Qi Z, Wang L, Desai K, Cogswell J, Stern M, Lawson B, et al.
J Mol Diagn
. 2019 Jul;
21(5):796-807.
PMID: 31255795
Clinical biomarker studies are often hindered by the scarcity or suboptimal quality of biological specimens. EdgeSeq, a transcriptomics analysis platform, combines quantitative nuclease protection assay technology with next-generation sequencing, using...
5.
Hellmann M, Callahan M, Awad M, Calvo E, Ascierto P, Atmaca A, et al.
Cancer Cell
. 2019 Feb;
35(2):329.
PMID: 30753829
No abstract available.
6.
Skoulidis F, Goldberg M, Greenawalt D, Hellmann M, Awad M, Gainor J, et al.
Cancer Discov
. 2018 May;
8(7):822-835.
PMID: 29773717
is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that (KL) or (KP) comutations define distinct subgroups of -mutant LUAC. Here, we examine the efficacy of...
7.
Hellmann M, Callahan M, Awad M, Calvo E, Ascierto P, Atmaca A, et al.
Cancer Cell
. 2018 May;
33(5):853-861.e4.
PMID: 29731394
Durable responses and encouraging survival have been demonstrated with immune checkpoint inhibitors in small-cell lung cancer (SCLC), but predictive markers are unknown. We used whole exome sequencing to evaluate the...
8.
Hellmann M, Nathanson T, Rizvi H, Creelan B, Sanchez-Vega F, Ahuja A, et al.
Cancer Cell
. 2018 Apr;
33(5):843-852.e4.
PMID: 29657128
Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequencing to examine non-small-cell lung cancer (NSCLC) treated...
9.
Yang H, Douglas G, Monaghan K, Retterer K, Cho M, Escobar L, et al.
Cold Spring Harb Mol Case Stud
. 2016 May;
1(1):a000562.
PMID: 27148574
Whole-exome sequencing (WES) represents a significant breakthrough in clinical genetics, and identifies a genetic etiology in up to 30% of cases of intellectual disability (ID). Using WES, we identified seven...
10.
Ye Y, Cho M, Retterer K, Alexander N, Ben-Omran T, Al-Mureikhi M, et al.
Cold Spring Harb Mol Case Stud
. 2016 May;
1(1):a000455.
PMID: 27148570
Seven patients with similar phenotypes of developmental delay and microcephaly were found by whole-exome sequencing to have de novo loss-of-function mutations in POGZ. POGZ is a pogo transposable element-derived protein...